Free Trial
→ Forget Tesla — This Tiny AI Stock Is Musk’s Real Play (From Behind the Markets) (Ad)tc pixel Free AZN Stock Alerts

AstraZeneca (AZN) Stock Forecast & Price Target

AstraZeneca logo
$81.75 -0.03 (-0.03%)
As of 03:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy
Based on 5 Analyst Ratings
Sell
0
Hold
1
Buy
4

Based on 5 Wall Street analysts who have issued ratings for AstraZeneca in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 5 analysts, 1 has given a hold rating, and 4 have given a buy rating for AZN.

Consensus Price Target

$86.00
5.20% Upside
According to the 5 analysts' twelve-month price targets for AstraZeneca, the average price target is $86.00. The highest price target for AZN is $97.00, while the lowest price target for AZN is $75.00. The average price target represents a forecasted upside of 5.20% from the current price of $81.75.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for AZN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AZN Analyst Ratings Over Time

TypeCurrent Forecast
9/5/24 to 9/5/25		1 Month Ago
8/6/24 to 8/6/25		3 Months Ago
6/7/24 to 6/7/25		1 Year Ago
9/6/23 to 9/5/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
Buy
4 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
6 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$86.00$89.00$85.00$89.75
Forecasted Upside5.20% Upside20.92% Upside16.63% Upside8.13% Upside
Consensus RatingModerate BuyModerate BuyBuyModerate Buy

AZN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AstraZeneca Stock vs. The Competition

TypeAstraZenecaMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside5.16% Upside15,814.56% Upside10.57% Upside
News Sentiment Rating
Positive News

See Recent AZN News
Positive News
Positive News
Export to Excel
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
7/9/2025Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Luisa Hector
Not Rated
Set Target$97.00+37.02%
4/15/2025BNP Paribas
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
P. Verdult
Not Rated
Initiated CoverageOutperform$75.00+11.09%
2/13/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
M. Weston
Not Rated
UpgradeNeutral ➝ Buy
2/12/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Initiated CoverageOverweight
11/6/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 UpgradeSell ➝ Hold
9/11/2024Erste Group Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 UpgradeHold ➝ Buy
8/12/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Boost TargetBuy$90.00 ➝ $95.00+16.29%
6/24/2024Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
P. Verdult
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
UpgradeStrong-Buy
6/24/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
E. Field
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
UpgradeStrong-Buy
5/30/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Boost TargetBuy$80.00 ➝ $85.00+10.72%
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Initiated CoverageBuy$97.00+27.50%
4/26/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Boost TargetOutperform$80.00 ➝ $82.00+8.70%
1/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 DowngradeBuy ➝ Hold
12/18/2023HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Initiated CoverageBuy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:16 PM ET.


Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 3, 2025. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AstraZeneca
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in AstraZeneca:

  • The current stock price is around $80, reflecting a stable market position and potential for growth.
  • AstraZeneca has shown strong revenue growth, with a recent quarterly revenue increase of over 16% compared to the previous year, indicating robust demand for its products.
  • The company has a solid market capitalization of approximately $248 billion, suggesting a strong financial foundation and investor confidence.
  • Analysts have rated AstraZeneca with a "Moderate Buy" consensus, with a target price of $86, indicating potential upside for investors.
  • AstraZeneca's recent earnings report met analysts' expectations, showcasing its ability to maintain profitability in a competitive market.

AstraZeneca
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in AstraZeneca for these reasons:

  • The stock has experienced fluctuations, with a 52-week high of $87.68 and a low of $61.24, indicating volatility that may concern risk-averse investors.
  • AstraZeneca recently cut its dividend, which may signal financial caution and could deter income-focused investors.
  • The company's price-to-earnings (P/E) ratio is around 30, which may be considered high compared to industry averages, suggesting that the stock could be overvalued.
  • With a beta of 0.36, AstraZeneca's stock is less volatile than the market, which may limit potential gains during bullish market conditions.
  • Institutional investors own over 20% of AstraZeneca's stock, which could lead to significant price movements if these investors decide to sell.

AZN Forecast - Frequently Asked Questions

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is $86.00, with a high forecast of $97.00 and a low forecast of $75.00.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There is currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AZN shares.

According to analysts, AstraZeneca's stock has a predicted upside of 5.20% based on their 12-month stock forecasts.

AstraZeneca has been rated by research analysts at Berenberg Bank in the past 90 days.

Analysts like AstraZeneca more than other "medical" companies. The consensus rating score for AstraZeneca is 2.80 while the average consensus rating score for "medical" companies is 2.78. Learn more on how AZN compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NASDAQ:AZN) was last updated on 9/5/2025 by MarketBeat.com Staff
From Our Partners
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...
Stansberry Research | Sponsoredtc pixel
“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...
InvestorPlace | Sponsoredtc pixel
How “Trump’s New Dollar” Could Impact Your Wealth
President Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...
Brownstone Research | Sponsoredtc pixel
Forget Tesla — This Tiny AI Stock Is Musk’s Real Play
While Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...
Behind the Markets | Sponsoredtc pixel
This Coin Could Explode, and it’s Hiding in Plain Sight!
The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...
Crypto 101 Media | Sponsoredtc pixel
Retire Comfortably with These New Monthly Income ETFs?
Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...
Investors Alley | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...
SmartAsset | Sponsoredtc pixel
Warren Buffett Issues Cryptic Warning on U.S. Dollar
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...
Banyan Hill Publishing | Sponsoredtc pixel